We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation of TRAIL receptors, which can sustain TRAIL-induced apoptosis for a long time. Here, we designed a replication-defective adenovirus expressing the short hairpin RNA (shRNA) against c-Cbl to test the possibility of developing a cancer gene therapy that can act as a sensitizer of TRAIL. As expected from the results of our previous study that used a stable cell line with downregulated c-Cbl, infection with the c-Cbl shRNA-expressing adenovirus led to an increase in the death receptor 4 (DR4) and DR5 levels, which is known to be a cause for the increase of TRAIL-induced apoptosis. In conclusion, we demonstrated that c-Cbl shRNA-expressing adenovirus is able to sensitize TRAIL-induced apoptosis in vivo as well as in vitro.
INTRODUCTION
Cbl is a well-known multiadaptor protein involved in ligandinduced downregulation of receptor tyrosine kinases. 1 In mammals, three Cbl proteins encoded by separate genes have been identified: c-Cbl, Cbl-b and Cbl-c (also known as Cbl-3). 2, 3 These isoforms are encoded on different chromosomes and show distinct tissue expression. [4] [5] [6] However, all three share highly conserved regions in their N-terminal halves, which encompass their tyrosine kinase binding, linker and RING-(really interesting new gene) finger domains. In contrast, the C-terminal regions of these family members are less well conserved, but share a common characteristic, which is the ability to interact with a range of Src homology 2-and Src homology 3-domain-containing proteins. 7 Especially, c-Cbl and Cbl-b show a similar ability to act as ubiquitin ligase? Previously, we observed that c-Cbl interacts with the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and regulates their levels through the proteosomal and lysosomal pathways, and this c-Cbl-mediated degradation of TRAIL receptors is responsible for the early phase of acquired TRAIL resistance. 8 In addition to being responsible for TRAIL resistance through receptor degradation, c-Cbl also acts as a mediator of Srcinduced phosphatidylinositol 3-kinase-Akt signaling activation after TRAIL treatment. 9 A recent study performed on the basis of the survival potential of c-Cbl showed that downregulation of c-Cbl family caused an increase in death receptors 4/5 (DR4/5) and resultant sensitization of TRAIL-induced apoptosis. 10 To demonstrate that c-Cbl downregulation can increase TRAILinduced apoptosis in cancer cells both in vitro and in vivo, a defective adenovirus-expressing short hairpin RNA (shRNA) against c-Cbl was developed. Here, we used a type of shRNAexpressing adenoviral vector because as McAnuff et al. 11 indicated, shRNA-mediated knockdown was more potent than small interfering RNA on a molar basis, and the adenoviral vector is widely used to introduce genes into cancer cells because of its relatively higher transduction efficiency than other viral and nonviral vectors and its ability to transduce foreign genes stably in vivo. In addition, the adenoviral vector is efficient in delivering genes both to dividing and non-dividing cells, with the chances of mutations being rare. 12, 13 In this study, we investigated the effectiveness of a c-Cbl shRNA-expressing adenoviral vector in treating cancer cells with TRAIL.
MATERIALS AND METHODS

Cell culture
The human prostate adenocarcinoma cell line, DU-145 (ATCC HTB-81; ATCC, Manassas, VA, USA), was cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (HyClone, Logan, UT, USA) and 26 mM sodium bicarbonate. The cells were maintained in a humidified environment containing 5% CO 2 at 37 1C.
Reagents and antibodies
Antibodies to c-Cbl and poly (ADP-ribose) polymerase (PARP) were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibodies to DR4, DR5 and actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-adenovirus type 5 (Ad5) antibody was purchased from Abcam (Cambridge, UK), and all other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).
Selection of shRNA against c-Cbl
To construct shRNA against c-Cbl, two different kinds of c-Cbl shRNA were selected. One was obtained from the c-Cbl shRNA used in pSilencer 2.1-U6 hygro/c-Cbl shRNA. 8 The target sequence was 5 0 -GATGGA GACACTTGGAGAA-3 0 and the loop sequence was 5 0 -TTCAAGAGA-3 0 , which was originally used in 2002.
14 For the expression of c-Cbl shRNA 1 in adenovirus, the top strand sequence (5 0 -GATCCGATGGAGACACT TGGAGAATTCAAGAGATTCTCCAAGTGTCTCCATCTTTTTTGGAAA-3 0 ) and the bottom strand sequence (5 0 -AGCTTTTCCAAAAAAGATGGAGACACTTGGAGA ATCTCTTGAATTCTCCAAGTGTCTCCATCG-3 0 ) was selected. After annealing, the sequences were inserted into the pSP72DE3-U6 vector, which is an adenoviral shuttle vector. The other shRNA against c-Cbl was obtained by screening several candidates of shRNA sequences. The selected target sequence was 5 0 -ATGCTGGCAGAACTAAAAGGAATCT-3 0 , and the selected loop sequence was 5 0 -TCTC-3 0 . For the expression of c-Cbl shRNA in adenovirus, the top strand sequence (5 0 -GATCCGTGCTGGCAGAACTAAA AGGAATCTTCTCAGATTCCTTTTAGTTCTGCCAGCATTTTT-3 0 ) and the bottom strand sequence (5 0 -AGCTTAAAAATGCTGGCAGAACTAAAAGGAATCTGAG AAGATTCCTTTTAGTTCTGCCAGCAT-3 0 ) was selected and then annealed for subcloning into pSP72DE3-U6.
Construction of the recombinant adenovirus
The adenoviral shuttle vector, pCA14 (Microbix, Mississauga, Ontario, Canada), which contained the IX gene of Ad5, was linearized by XmnI digestion. The adenoviral vector dl324-BstBI, in which nucleotides 340-4641 of Ad5 in the E1 region and nucleotides 28 592-30 470 of Ad5 in the E3 region were deleted, was linearized by BstBI digestion. The linearized vectors were cotransformed into Escherichia coli BJ5183 for homologous recombination. The resultant homologous recombinant adenoviral plasmid was named as dl324-IX. The shRNA construct and the U6 promoter were subcloned into the pSP72DE3-U6 E3 shuttle vector. The adenoviral shuttle vector, pSP72DE3-U6-shRNA, was linearized by XmnI digestion. The adenoviral vector dl324-IX was linearized by SpeI digestion. The linearized vectors were cotransformed into E. coli BJ5183 for homologous recombination. The resultant homologous recombinant adenoviral plasmids dl324-IX-DE3-U6-shNC (NC, negative control; scrambled sequences) and dl324-IX-DE3-U6-shCbl were digested with PacI and transfected into human embryonic kidney 293 cells to generate a replication-incompetent adenovirus. The infectious titer of the adenovirus sample was determined by a limiting dilution assay using the AdEasy Adenoviral Vector System (Qbiogene, Carlsbad, CA, USA).
Western blot analysis DU-145 was transfected with the E3 shuttle vector or infected with recombinant adenovirus. After 2 days, cells were lysed with 1 Â Laemmli lysis buffer (62.5 mM Tris, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 0.002% bromophenol blue) and the protein concentration was determined using the BCA Protein Assay Kit (Thermo Scientific, Fremont, CA, USA). Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the gels were then electrotransferred onto a polyvinylidene difluoride membrane (Millipore, Billerica, MA, USA). Immunodetection was performed with anti-Cbl, anti-PARP and anti-b-actin antibodies by using the chemiluminescent and fluorescent image analysis system (Syngene, Cambridge, UK).
Real-time polymerase chain reaction DU-145 cells were infected with the recombinant adenovirus with various multiplicity of infections (MOIs). After 2 days, cells were lysed with Trizol reagent (Life Technologies, Carlsbad, CA, USA) and the total RNA was isolated by using chloroform. The RNA concentration was determined by using the Nanodrop 2000 (Thermo Scientific).
The real-time polymerase chain reaction (PCR) reaction was performed using the Power SYBR Green RNA-to-C T 1-Step Kit (Life Technologies). The reaction mixture contained the reverse transcriptase enzyme mix, reverse transcription PCR mix, forward primer, reverse primer, RNA template and nuclease-free water. c-Cbl cDNA was amplified using the forward primer, 5 0 -GTGATCCCTGGACAGGAAGA-3 0 , and the reverse primer, 5 0 -CATTGGC AGATGAGGAAGGT-3 0 . b-Actin was amplified using the forward primer, 5 0 -ACTCTTCCAGCCTTCCTTC-3 0 , and the reverse primer, 5 0 -ATCTCCTTCT GCATCCTGTC-3 0 .
Immunohistochemistry
Immunohistochemistry studies were performed on paraffin-embedded tumor tissues using anti-c-Cbl and anti-Ad5 antibodies to determine the expression of these proteins in the tumor tissue. The tumor tissue slides were deparaffinized by incubating in xylene for 10 min and rehydrated serially in alcohol (100, 90 and 70%). Endogenous peroxidase was blocked by incubation with 3% H 2 O 2 for 15 min at room temperature, and antigen retrieval was achieved by incubating the slides in citrate buffer for 10 min in a steamer. For permeabilization, the slides were incubated in phosphatebuffered saline (PBS) containing 0.5% Triton X-100 for 30 min and then washed three times with PBS. To reduce nonspecific background staining due to endogenous peroxidases, the slides were incubated with a hydrogen peroxide block (Thermo Scientific) for 10 min. After washing, an ultra V block (Thermo Scientific) was applied to the slides for 5 min at room temperature to further block nonspecific background staining. The slides were incubated with an anti-c-Cbl antibody (1:500 dilution; Cell Signaling Technology) and an anti-Ad5 antibody (1:800 dilution; Abcam) for 12 h at 4 1C and further with a horseradish peroxidase polymer (Thermo Scientific) for 15 min at room temperature. To detect protein expression, the tissue sections were stained with diaminobenzidine tetrahydrochloride and minimally counterstained with hematoxylin (for visualization of antigen-antibody complexes). Sections were mounted under a coverslip using an aqueous mounting solution (shandon synthetic mountant (thermo scientific) þ xylene ¼ 1:1)
Animal study ) for 2 h, and cell apoptosis was determined by microscopic analysis.
of PBS alone. After a day, the mice were given intratumoral injections of TRAIL (20 mg/100 ml). This injection regimen was repeated three times, and tumor growth was measured every 3 days for a month using a caliper. Tumor volume (V) was calculated using the formula: V (mm 3 ) ¼ 0.52 Â length (mm) Â width (mm) 2 .
Statistical analysis
Data were presented as mean±standard error (s.e.m.), and the significance of differences between groups was determined by Student's t-test. P-values were calculated using Microsoft Excel (2010). A value of Po0.05 was considered as statistically significant.
RESULTS
Specific silencing effect of Cbl shRNA A previous study identified an shRNA sequence that was shown to be effective in the silencing of human c-Cbl mRNA. 8 In this study, five other oligomers of c-Cbl shRNA as well as control shRNA (shRNA against luciferase) were also validated using real-time PCR after selection of the appropriate c-Cbl target sequences, and the target sequence with maximal repression was identified. As shown in Figures 1a and b , among the five validated c-Cbl shRNAs (designated from c-Cbl sh1-5), c-Cbl sh3 showed the greatest reduction of c-Cbl mRNA levels (76%). For the convenience of comparison of previously identified shRNA with this selected c-Cbl sh3 construct, they were newly named as shCbl 1 for c-Cbl shRNA of pSilencer 2.1-U6 hygro and shCbl 2 for c-Cbl sh3, respectively. To construct a defective adenovirus, the c-Cbl shRNA sequences were inserted into the pSP72DE3-U6 E3 shuttle vector (Figure 1b) . The silencing effect of the shCbl 1 construct has been confirmed in our previous publication. 8 We found that the effect of Cbl downregulation by the pSP72DE3-U6-shCbl 1 plasmid was stronger than that by the pSP72DE3-U6-shCbl 2 plasmid. Figure 1c shows that the shCbl 1-expressing adenovirus was more effective in the suppression of c-Cbl mRNA compared with the shCbl 2-expressing adenovirus. This differential suppression of c-Cbl mRNA was also reflected at the protein level (Figure 1d ).
Effect of shCbl-expressing replication-incompetent adenovirus on the c-Cbl protein expression and TRAIL-induced apoptosis For the induction of efficient c-Cbl silencing by the shRNA Cbl-expressing adenovirus, we introduced an shCbl construct under the control of an U6 promoter in the E3 region of an E1A, E1B double-deleted adenovirus (dl324-IX). The replication-incompetent adenoviruses (dl324-IX-DE3-U6-NC, dl324-IX-DE3-U6-shhCbl 1 and dl324-IX-DE3-U6-shhCbl 2) were generated by homologous recombination.
To compare the effect of dl324-IX-DE3-U6-shhCbl 1 and dl324-IX-DE3-U6-shhCbl 2 on TRAIL-induced apoptosis, DU-145 cells were infected with dl324-IX-DE3-U6-NC, dl324-IX-DE3-U6-shhCbl 1 or dl324-IX-DE3-U6-shhCbl 2 viruses at an MOI of 1, 10, 20 and 50. Figure 2a (left panel) showed that the dl324-IX-DE3-U6-shhCbl 1 adenovirus significantly reduced c-Cbl expression compared with the dl324-IX-DE3-U6-shhCbl 2 adenovirus. As shown in Figure 2a (right panel), there was an increase in TRAIL-induced apoptosis only when the cells were infected with the dl324-IX-DE3-U6-shCbl 1 adenovirus. These results were strengthened by the morphological changes in the cancer cells (Figure 2b ).
Sensitization of TRAIL-induced apoptosis by c-Cbl shRNAexpressing adenovirus through an increase in DR4/ 5 We further demonstrated that the increase in TRAIL-induced apoptosis as a result of reduced c-Cbl levels was related to the increased levels of the TRAIL receptors (DR4/5). As mentioned earlier, the multiadaptor protein c-Cbl is involved in TRAIL-induced downregulation of the TRAIL receptor, 8 suggesting that c-Cbl downregulation rather increases DR4/5, making cells more sensitive to TRAIL-induced apoptosis. Accordingly, DR4 and DR5 levels were dramatically increased in DU-145 cells after infection with the shCbl 1-expressing adenovirus (Figure 3) .
Effect of Cbl silencing in a xenograft model of prostate cancer Our next aim was to demonstrate the effect of the TRAIL-injected dl324-IX-DE3-U6-shhCbl 1 adenovirus on a DU-145 xenograft model. For this, tumor growth was measured for 30 days after an intratumoral injection of TRAIL in a DU-145 mouse tumor model infected with Cbl 1 shRNA-expressing adenovirus. Figure 4a confirmed the adenovirus infection and effective downregulation of c-Cbl and Figure 4b shows that TRAIL-injected dl324-IX-DE3-U6-shhCbl 1 adenovirus markedly inhibits tumor growth compared with other experimental groups (PBS þ TRAIL, dl324-IX-DE3-U6-NC virus þ PBS, dl324-IX-DE3-U6-NC virus þ TRAIL and dl324-IX-DE3-U6-shCbl 1 virus þ PBS) (P ¼ 0.028).
DISCUSSION
In this study, we used two different structures of human c-Cbl shRNA for in vitro and in vivo experiments. One of these structures was from an shRNA sequence reported in our previous publication, 8 and the other one was derived from a screening algorithm. A major difference is that the former shRNA structure has a loop sequence of 5 0 -TTTAAGAGA-3 0 , as described in Brummelkamp et al., 14 and the latter has a loop sequence of 5 0 -TCTC(TC)-3 0 . Although it is known that the loop sequence of shRNA is an essential part of the shRNA design, 15 it is still difficult to predict the silencing efficacy solely based on the algorithm, without consideration of the mRNA secondary structure. Because we found some other target sequences selected by the same algorithm to be effective (data not shown), the mRNA secondary structure can be considered to be an important factor in predicting gene silencing efficacy of shRNA. 16 Our results showed that an incomplete suppression of c-Cbl did not sensitize TRAIL-induced apoptosis (Figure 2 ), suggesting that a threshold level is required to trigger the induction of apoptosis. However, in the animal model, tumor cells continued to grow even after being infected with an shCbl1-expressing adenovirus (Figure 4b ). This can be caused by at least two possibilities. One is related to the incomplete suppression due to the existence of Cbl isotypes. Considering that c-Cbl and Cbl-b show a similar ability to act as E3 Ub ligases and share a common range of substrates, 7, 17 the suppression of c-Cbl could be compensated by Cbl-b, causing degradation of the TRAIL receptors DR4/5 and resulting in the development of resistance to TRAIL-induced apoptosis. Similar phenomena have been reported in Akt isoforms, in which the loss of Akt1 promoted cellular invasiveness and metastasis. This can be caused by a shift of balance in Akt2 signaling 18 or in between the Ras-extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase-mammalian target of rapamycin pathways, where one pathway is blocked, thereby activating the other pathway through releasing the cross-inhibition. 19 Another possibility is the defective adenoviral vector system by which c-Cbl downregulation occurs only in the infected cells, which means that TRAIL can efficiently kill the tumor cells within a limited area of virus infection. As a result, tumor size becomes increased again after tumor retardation for a while in mouse model. This weakness of defective adenoviral vector system could be the main cause of low therapeutic effect in vivo in spite of the effective downregulation of c-Cbl protein and apoptotic cell death in vitro (Figures 2 and 3 ). To overcome this drawback, the effectiveness of oncolytic adenovirus expressing both the shRNAs (c-Cbl/Cbl-b) along with TRAIL is currently under investigation. Mice harboring the established tumors were injected as described in section a. After 9 or 15 days of the tumors with three cycles of injection, tumor sizes were measured. Error bars represent the standard error from four mice of each experimental group.
[shhCbl þ TRAIL] group shows a significant tumor growth inhibition compared with [NC þ PBS] control group at day 15 only. The asterisk indicates a significant difference compared with control (P ¼ 0.028).
